论文部分内容阅读
目的 :探讨SATB1(special AT rich sequence-binding protein-1)、survivin和血管内皮生长因子(vascular endothelial growth factor,VEGF)在卵巢上皮癌中的表达及其临床意义。方法 :应用免疫组织化学法检测正常卵巢、卵巢浆液性囊腺瘤和卵巢上皮癌组织中SATB1、survivin和VEGF的表达,并分析SATB1、survivin和VEGF的表达与卵巢上皮癌患者临床病理特征及预后之间的关系。结果 :卵巢上皮癌组织中SATB1、survivin和VEGF的阳性表达率均显著高于卵巢浆液性囊腺瘤和正常卵巢组织(P值均<0.05)。SATB1的表达与卵巢上皮癌患者有无淋巴结转移和有无腹腔积液有关(P值均<0.05)。SATB1、survivin和VEGF阳性表达患者的中位生存时间短于阴性表达患者(P值均<0.05)。SATB1、survivin、VEGF及国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)分期是卵巢上皮癌患者预后的独立影响因子(P值均<0.01)。结论 :卵巢上皮癌组织中SATB1、survivin和VEGF的阳性表达率较高,且SATB1的表达与患者有无淋巴结转移和有无腹腔积液有关,SATB1、survivin和VEGF阳性表达的卵巢上皮癌患者的预后较差。
Objective: To investigate the expression and clinical significance of SATB1, survivin and vascular endothelial growth factor (VEGF) in epithelial ovarian cancer. Methods: The expressions of SATB1, survivin and VEGF in normal ovary, ovarian serous cystadenocarcinoma and ovarian epithelial carcinoma tissues were detected by immunohistochemistry. The expressions of SATB1, survivin and VEGF were analyzed with the clinicopathological features and prognosis of patients with epithelial ovarian cancer The relationship between. Results: The positive rates of SATB1, survivin and VEGF in ovarian epithelial carcinoma were significantly higher than those in ovarian serous cystadenoma and normal ovarian tissue (P <0.05). The expression of SATB1 was associated with lymph node metastasis and with or without ascites in patients with epithelial ovarian cancer (all P <0.05). The median survival time of SATB1, survivin and VEGF positive patients was shorter than that of negative patients (P <0.05). The staging of SATB1, survivin, VEGF and International Federation of Gynecology and Obstetrics (FIGO) were independent prognostic factors in patients with epithelial ovarian cancer (P <0.01). Conclusion: The positive rates of SATB1, survivin and VEGF in epithelial ovarian cancer tissues are high, and the expression of SATB1 is related to the presence or absence of lymph node metastasis and the presence or absence of ascites in patients with epithelial ovarian cancer. The expressions of SATB1, survivin and VEGF in patients with epithelial ovarian cancer Poor prognosis.